CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity

Nine patients completed all three psilocybin treatments; one patient missed the third dose for logistical reasons but completed the rest of the study. The dosing regimen was described as well tolerated, with no serious adverse reactions reported. Acute subjective psychedelic effects varied between participants, and the researchers noted no meaningful blood pressure changes. One patient reported no subjective psychedelic effects and also showed the lowest maximum plasma psilocin level. Another patient reported beneficial psychological effects lasting at least 6 months. The primary clinical finding was a statistically significant reduction in attack frequency from baseline to follow-up. The extracted text states that headache frequency was reduced, and elsewhere specifies a mean reduction of 31% (SD 31), with p FWER = 0.008. The summary fragment from the results section also indicates that average attack duration was assessed, but the extracted text does not clearly report a definitive statistical outcome for duration. One patient experienced complete remission lasting 21 weeks, and the paper also notes that one patient had a 22% reduction in attack frequency despite no clear psychedelic effects. In the neuroimaging results, the researchers found three clusters with significant positive functional connectivity to the hypothalamic seed across baseline and follow-up scans: a large diencephalic cluster including the hypothalamus, thalamus, caudate, and brain stem; a cluster in the left lingual gyrus; and a cluster in the right cerebellum. One cluster in occipito-temporal white matter showed negative functional connectivity. The key association was a negative correlation between the percent reduction in attack frequency and changes in hypothalamic-diencephalic connectivity, with p FWER = 0.03 and R = -0.81, meaning that larger increases in this connectivity were associated with larger reductions in attacks. By contrast, the exploratory network-level analysis did not show statistically significant baseline-to-follow-up changes in within- or between-network connectivity across the seven tested networks, and no significant associations were found between percentage change in headache frequency and network connectivity changes. The paper also reports substantial interindividual variability in plasma psilocin levels, but the extracted text does not clearly present a full dose-response analysis.

The authors interpret the study as preliminary evidence that psilocybin may have prophylactic potential in chronic cluster headache and that the hypothalamus, particularly hypothalamic-diencephalic circuitry, may be involved in treatment response. They argue that the observed reduction in attack frequency, together with the correlation between clinical improvement and changes in hypothalamic connectivity, supports a possible role for this neural pathway. They also suggest that the benefit may not depend entirely on acute psychedelic effects, because one patient without clear subjective psychoactive effects still showed a reduction in attacks. In relation to earlier research, the authors note that their findings are broadly consistent with prior observational reports and a recent small placebo-controlled trial that also suggested benefit in chronic cluster headache. They compare the average reduction in attacks in their study with that previously reported and state that the results together support the need for larger trials. They also discuss earlier neuroimaging work indicating altered hypothalamic-diencephalic connectivity in cluster headache, which they believe aligns with their findings. The paper emphasises several limitations. The sample was very small, making the findings exploratory. Participants were treatment-refractory and recruited from a tertiary headache centre, which may limit generalisability. Prophylactic medication was not allowed, so the findings may not apply to patients taking standard preventive therapy. The authors also note that they used a fixed body-weight-based dose and that higher doses might produce different effects. The extracted text cuts off before the end of the limitations discussion, so additional limitations may have been present but are not visible here. In terms of implications, the authors caution that the results are preliminary and advise against self-medication with psychedelics, noting that psilocybin remains illegal in most countries and can cause harm in uncontrolled settings. They suggest that psilocybin, or potentially non-psychedelic 5-HT2A receptor agonists, could become useful for CCH or other chronic pain conditions, but only after further research establishes safety, efficacy, and mechanisms more firmly.